Showing 4851-4860 of 8787 results for "".
- Cynosure Expands Its Potenza RF Microneedling System with New Fusion Tip for Enhanced Topical Penetrationhttps://practicaldermatology.com/news/cynosure-expands-its-potenza-rf-microneedling-system-with-new-fusion-tip-for-enhanced-topical-penetration/2460781/The Fusion Tip is the latest addition to Cynosure's Potenza system, its four-mode RF microneedling device, which uses ultrafine needles and RF energy to penetrate the top layer of the skin, triggering the body's natural healing process to regenerate new collagen and elastin.
- Sirnaomics Starts Phase 2b Study of STP705 for SCChttps://practicaldermatology.com/news/sirnaomics-inc-starts-phase-2b-study-of-stp705-for-scc/2460778/Sirnaomics, Inc. is initiating a Phase 2b study of STP705 for the treatment of squamous cell skin cancer. STP705 is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery
- Accure Acne Seeks to Raise Up To $20 Million Through Private Placement Offeringhttps://practicaldermatology.com/news/accure-acne-seeks-to-raise-up-to-20-million-through-private-placement-offering/2460776/Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million. Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an&n
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- Burt's Bees Nature-Based Ingredients Protect Against Evolving Skincare Challengeshttps://practicaldermatology.com/news/burts-bees-nature-based-ingredients-protect-against-evolving-skincare-challenges/2460772/Burt's Bees bakuchiol bests retinol when it comes to promoting expression of certain anti-aging genes, according to a poster presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. And other new research supports the moisturization and skin barrier benefits
- New Studies Support Taltz’s Role in Treating Psoriasishttps://practicaldermatology.com/news/new-studies-support-taltzs-role-in-treating-psoriasis/2460771/Lilly's Taltz delivers more cumulative days with completely clear skin for adults with psoriasis, compared to seven other biologics. What’s more, Taltz also helped patients stay on treatment longer and have more days without additional therapy in three real-world analyses of U
- Dermavant: Posters Unveil Additional Data for Once-Daily Topical Tapinarofhttps://practicaldermatology.com/news/dermavant-posters-unveil-additional-data-for-once-daily-topical-tapinarof/2460770/Dermavant Sciences will present data in poster form from its two pivotal phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, at AAD VMX 2021. Tapinarof is a novel, once-daily therapeutic aryl hydrocarbon recepto
- Visible Light from the Sun Causes Pigmentary Skin Changeshttps://practicaldermatology.com/news/visible-light-from-the-sun-causes-pigmentary-skin-changes/2460768/Visible light from the sun plays a significant role in causing pigmentary skin changes, particularly in people with skin of color, according to information presented at AAD VMX 2021. “We know from decades of research that unprotected exposure to ultraviolet light from the sun can
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec